Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (11059)	3/6/2017 4:10:06 PM
From: tuck	Read Replies (2) \| Respond to of 12215

TGTX: I was tempted to sell when it hit double digits. With no OS data, I wonder about the marketability of the combo. Any thoughts about that? I still hold out hope the their delta inhibitor has efficacy to go with the safety; success with ublituximab would be icing on the cake. It's not a huge position for me. Neither is PIRS. The only bear case I'm aware of is that the lead program could be commercially obviated if FGEN is successful, as roxadustat also seems to hit hepcidin in a helpful way, and is closer to commercialization. Good to have you kicking the tires. I haven't looked closely at the abstract data versus what's already been published about 343, and probably won't get to it till tomorrow. What did you see that you liked there? Edit: forgot, I actually sold PIRS a few days ago given the above stated bear case. Oh, well, at least the charity portfolio will benefit from today's news. TIA & Cheers, Tuck

To: Biotech Jim who wrote (11059)	3/6/2017 6:50:17 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 12215

>> what am I missing as to the bear case? << I don't have a clue. How much data do they have addressing potential immunogenicity? There are only a few anticalins in man. whereas there are millions of immunoglobulin hypervariable regions expressed. Presumably, repeat dosing in primates looked ok? Tuck, have the phase I hepcidin results been summarized anywhere? Was there repeat dosing? Are "duocalins" going to face additional issues re. immunogenicity? A few publications talk about PEGlylation to extend half-lives, but I can't find any indication of how short they are. I don't expect anyone to go out and dig up answers, particularly you, Jim. Just throwing stuff out.

To: Biotech Jim who wrote (11059)	6/24/2017 3:44:19 PM
From: tuck	Read Replies (1) \| Respond to of 12215

PIRS: Latest corporate presentation, from a few days ago. Pieris Corporate Presentation I pay particular attention to development milestone timing, and these are towards the end. One near term one is the initiation of P1 for PRS-343, as that is supposed to be in the nearly ended first half of this year. There's another P1 initiation expected in the second half. Neither of these are big value drivers, IMO, but do highlight management's ability to execute or not. The biggie for this year will be towards the end, when they report P2a data for PRS-080, which could lead to partner Takeda exercising its option on the program for Asian countries. PIRS has had a good run this year, about a three bagger for my charity portfolio; it's helping me stay in the hunt. I feel as though it's gotten away from me a bit, but it's mostly because they signed a deal. I would buy a pullback that wasn't on bad news, but still wonder what roxadustat means for PRS-080. Any of you guys have thoughts on that? And still wondering what you saw, BJ, in doing your DD on abstract data and such. Cheers, Tuck

To: Biotech Jim who wrote (11059)	8/9/2018 9:33:44 AM
From: tuck	1 Recommendation Recommended By scaram(o)uche Read Replies (2) \| Respond to of 12215

Pieris (PIRS) off some premarket following earnings, as Sanofi and Roche return rights to a couple of early programs. Given how terrible the antibiotics field is, the return of the p. aeruginosa program by Sanofi shouldn't be a huge surprise. The return by Roche is of an I-O program against an undisclosed target. I doubt either event is any indictment of the technology, and other, more mature programs remain on track (though I'm still bearish on the hepcidin program). Given current burn, and allowing for some increase, they have a solid two years of cash. No position at present, but I've been watching, and am tempted to write some puts at this level. Edit: Wrote some puts just now. Cheers, Tuck